<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The presence of an enhanced <z:chebi fb="1" ids="17650">cortisol</z:chebi> secretion in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is debated </plain></SENT>
<SENT sid="1" pm="."><plain>In type 2 diabetic subjects, <z:chebi fb="1" ids="17650">cortisol</z:chebi> secretion was found to be associated with the complications and metabolic control of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated <z:chebi fb="1" ids="17650">cortisol</z:chebi> secretion in 170 type 2 diabetic subjects and in 71 sex-, age-, and BMI-matched nondiabetic subjects </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: In <z:hpo ids='HP_0000001'>all</z:hpo> subjects, we evaluated ACTH at 8:00 a.m. in basal conditions and serum <z:chebi fb="1" ids="17650">cortisol</z:chebi> levels at 12:00 p.m </plain></SENT>
<SENT sid="4" pm="."><plain>(F24) and at 9:00 a.m. after a 1-mg overnight <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> suppression test and 24-h urinary free <z:chebi fb="1" ids="17650">cortisol</z:chebi> (UFC) </plain></SENT>
<SENT sid="5" pm="."><plain>In diabetic patients, we evaluated the presence of <z:hpo ids='HP_0011010'>chronic</z:hpo> complications (incipient <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, asymptomatic <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, background <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, and silent <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients were subdivided according to the absence (group 1, n = 53) or presence (group 2, n = 117) of <z:mp ids='MP_0002055'>diabetes</z:mp> complications </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In group 2, UFC (125.2 +/- 4.6 nmol/24 h) and F24 (120.6 +/- 4.1 nmol/l) were higher than in group 1 (109.2 +/- 6.8 nmol/24 h, P = 0.057, and 99.7 +/- 6.1 nmol/l, P = 0.005, respectively) and in nondiabetic patients (101.7 +/- 5.9 nmol/24 h, P = 0.002, and 100.3 +/- 5.3 nmol/l, P = 0.003, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>In diabetic patients, the number of complications was associated with F24 (R = 0.345; P &lt; 0.0001) and <z:mp ids='MP_0002055'>diabetes</z:mp> duration (R = 0.39; P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Logistic regression analysis showed that the presence of <z:mp ids='MP_0002055'>diabetes</z:mp> complications was significantly associated with F24, sex, duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, and glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In type 2 diabetic subjects, hypothalamic-pituitary-adrenal activity is enhanced in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> complications and the degree of <z:chebi fb="1" ids="17650">cortisol</z:chebi> secretion is related to the presence and number of <z:mp ids='MP_0002055'>diabetes</z:mp> complications </plain></SENT>
</text></document>